نتایج جستجو برای: braf

تعداد نتایج: 7505  

Journal: :The American journal of surgical pathology 2012
Oskar Koperek Christoph Kornauth David Capper Anna Sophie Berghoff Reza Asari Bruno Niederle Andreas von Deimling Peter Birner Matthias Preusser

The V600E mutation of the B-type Raf kinase (BRAF) gene is a common event in papillary thyroid carcinoma (PTC) and seems to play a key role in the development and progression of this disease. We evaluated the expression of the mutated BRAF V600E protein in 144 cases of PTC using a novel mutation-specific antibody. Seventy-six PTCs (52.8%) showed unequivocal diffuse cytoplasmic expression of the...

Journal: :Experimental and molecular pathology 2014
Maya Saroufim Robert H Habib Rita Gerges Jad Saab Asif Loya Samir S Amr Salwa Sheikh Mohammad Satti Christian Oberkanins Ibrahim Khalifeh

BACKGROUND Selective BRAF inhibitors have shown dramatic results with regard to improving outcome in patients with melanoma. Testing the BRAF status in matched primary and metastatic melanomas to optimize individual targeted therapy is not well investigated. METHODS Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40...

Journal: :Endocrine-related cancer 2016
Seo Ki Kim Jung-Woo Woo Jun Ho Lee Inhye Park Jun-Ho Choe Jung-Han Kim Jee Soo Kim

It has been reported that papillary thyroid carcinoma (PTC) with chronic lymphocytic thyroiditis (CLT) is less associated with extrathyroidal extension (ETE), advanced tumor stage and lymph node (LN) metastasis. Other studies have suggested that concurrent CLT could antagonize PTC progression, even in BRAF-positive patients. Since the clinical significance of the BRAF mutation has been particul...

Journal: :Molecular cancer therapeutics 2015
Zhiyu Tang Xi Yuan Rong Du Shing-Hu Cheung Guoliang Zhang Jing Wei Yuan Zhao Yingcai Feng Hao Peng Yi Zhang Yunguang Du Xiaoxia Hu Wenfeng Gong Yong Liu Yajuan Gao Ye Liu Rui Hao Shengjian Li Shaohui Wang Jiafu Ji Lianhai Zhang Shuangxi Li David Sutton Min Wei Changyou Zhou Lai Wang Lusong Luo

Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive. Prior studies su...

Journal: :Seizure 2017
Yin-Xi Zhang Chun-Hong Shen Yi Guo Yang Zheng Jun-Ming Zhu Yao Ding Ye-Lei Tang Shuang Wang Mei-Ping Ding

PURPOSE Glioneuronal tumors (GNTs) are the most common histological type of brain tumors in patients who received epilepsy surgery, and part of them presented with BRAF V600E mutation. We aimed to verify the presence of the BRAF V600E mutation in epilepsy-associated GNTs from Chinese population and evaluate the association with clinical features. METHODS Data from 35 patients diagnosed with G...

2014
Marjon A Smit Gianluca Maddalo Kylie Greig Linsey M Raaijmakers Patricia A Possik Bas van Breukelen Salvatore Cappadona Albert JR Heck AF Maarten Altelaar Daniel S Peeper

Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibition sensitizes melanoma cells to BRAF inhibition. We found many proteins to be induced upon PLX472...

2013
Alastair J. King Marc R. Arnone Maureen R. Bleam Katherine G. Moss Jingsong Yang Kelly E. Fedorowicz Kimberly N. Smitheman Joseph A. Erhardt Angela Hughes-Earle Laurie S. Kane-Carson Robert H. Sinnamon Hongwei Qi Tara R. Rheault David E. Uehling Sylvie G. Laquerre

Mitogen-Activated Protein Kinase (MAPK) pathway activation has been implicated in many types of human cancer. BRAF mutations that constitutively activate MAPK signalling and bypass the need for upstream stimuli occur with high prevalence in melanoma, colorectal carcinoma, ovarian cancer, papillary thyroid carcinoma, and cholangiocarcinoma. In this report we characterize the novel, potent, and s...

2013
Lei An Wei Jia Yang Yu Ning Zou Li Liang Yanling Zhao Yihui Fan Jin Cheng Zhongcheng Shi Gufeng Xu Grace Li Jianhua Yang Hong Zhang

The RAF kinase family is essential in mediating signal transduction from RAS to ERK. BRAF constitutively active mutations correlate with human cancer development. However, the precise molecular regulation of BRAF activation is not fully understood. Here we report that BRAF is modified by Lys63-linked polyubiquitination at lysine 578 within its kinase domain once it is activated by gain of const...

2016
Shuang Wen Mei Li Zhi-Min Liu Li-Sha Liu Can Tian Xiao-Qing Shao Shen Lv

The EGFR-KRAS-BRAF-MEK-ERK (MAPK) pathway plays an important role in most cancers with close association of EGFR, KRAS or BRAF mutations with carcinogenesis and drug resistance. EGFR have been developed for molecular targeted therapy of various cancers. However, it remains to be determined whether aberration of this pathway is essential for the survival of clear cell renal cell carcinoma (CCRCC...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Alexander M Menzies Lauren E Haydu Lydia Visintin Matteo S Carlino Julie R Howle John F Thompson Richard F Kefford Richard A Scolyer Georgina V Long

PURPOSE Certain clinicopathologic features correlate with BRAF mutation status in melanoma including younger age and primary subtype. This study sought to determine the BRAF mutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. METHODS A prospectively assembled cohort of Australian patients ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید